Ajanta Pharma Limited (AJANTPHARM) Price & Analysis

Compare

5 Followers

AJANTPHARM Stock Chart & Stats

₹2920.85

-₹25.05(-0.84%)

At close: Jan 09 4:00 PM EST

₹2920.85

-₹25.05(-0.84%)

Day’s Range― - ―

52-Week Range₹2,022.05 - ₹3,041.10

Previous CloseN/A

Volume47.67K

Average Volume (3M)2.10K

Market Cap

₹368.64B

Enterprise Value₹379.02B

Total Cash (Recent Filing)₹6.14B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)36.3

Beta0.51

Next Earnings

Apr 30, 2026

EPS Estimate

20.85

Next Dividend Ex-DateN/A

Dividend Yield1.04%

Share Statistics

EPS (TTM)21.80

Shares Outstanding124,935,620

10 Day Avg. Volume2,991

30 Day Avg. Volume2,099

Financial Highlights & Ratios

PEG Ratio2.64

Price to Book (P/B)8.64

Price to Sales (P/S)7.05

P/FCF Ratio39.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹3,207.50

Price Target Upside9.81% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)88.06

Revenue Forecast (FY)₹53.79B

Bulls Say, Bears Say

Bulls Say

Strong Cash Flow GenerationConsistent and positive free cash flow growth and a favorable operating cash flow to net income ratio indicate durable internal funding for capex, product launches, and shareholder returns. This reduces reliance on external financing and supports multi-year reinvestment and stability.

Robust Revenue And Margin TrendsSustained revenue growth coupled with stable gross margins and improving net margins point to effective pricing, cost control, and product mix optimization. These structural margin drivers support long-term profitability and resilience across economic cycles.

Low Leverage, Solid Balance SheetA high equity ratio and low leverage provide financial flexibility to fund R&D, geographic expansion and weather sector headwinds. Improved ROE and steady asset growth underpin capacity to invest without materially increasing financing risk over the medium term.

Bears Say

Dependence On Regulatory ApprovalsInternational expansion and higher-value product launches depend on regulatory approvals and market access, creating multi-quarter execution risk. Delays or failures in registrations can slow revenue diversification and defer expected returns from new markets over several reporting periods.

Limited Investor CommunicationAbsence of earnings call disclosures and formal guidance reduces transparency into near-term operational drivers and management intent. Over time this can increase perceived information risk among long-term investors and make it harder to assess execution on strategy and recurring performance trends.

Undisclosed Segment/partner ConcentrationLack of disclosed segment-level revenue or partner/customer concentration data masks where growth or risk is concentrated. That opacity complicates assessment of reliance on particular markets, partners or products and raises structural exposure to localized regulatory or competitive shocks.

Ajanta Pharma Limited News

Ajanta Pharma Denies Involvement in Rumoured Restaurant Brands Asia Acquisition

An update from Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) is now available. Ajanta Pharma has issued a formal...

16d ago

Ajanta Pharma Publishes Q3 and Nine-Month FY26 Results in Newspapers in Line with SEBI Norms

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) has shared an update. Ajanta Pharma Limited has notified the stock exchanges...

24d ago

Ajanta Pharma to Engage Investors at Multiple February 2026 Conferences

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) just unveiled an update. Ajanta Pharma has announced its participation in multiple...

24d ago

Ajanta Pharma to Consider Interim Dividend Declaration

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) has provided an update. Ajanta Pharma Limited has announced that its Board...

4M ago

Ajanta Pharma to Consider Interim Dividend for FY 2026

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) has provided an update. Ajanta Pharma Limited has announced that its Board...

4M ago

Ajanta Pharma Reports Strong Q1 FY 2026 Financial Results

An update from Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) is now available. Ajanta Pharma Limited reported a robust...

7M ago

AJANTPHARM FAQ

What was Ajanta Pharma Limited’s price range in the past 12 months?

Ajanta Pharma Limited lowest stock price was ₹2022.05 and its highest was ₹3041.10 in the past 12 months.

What is Ajanta Pharma Limited’s market cap?

Ajanta Pharma Limited’s market cap is ₹368.64B.

When is Ajanta Pharma Limited’s upcoming earnings report date?

Ajanta Pharma Limited’s upcoming earnings report date is Apr 30, 2026 which is in 63 days.

How were Ajanta Pharma Limited’s earnings last quarter?

Ajanta Pharma Limited released its earnings results on Jan 30, 2026. The company reported ₹21.8 earnings per share for the quarter, beating the consensus estimate of ₹19.828 by ₹1.972.

Is Ajanta Pharma Limited overvalued?

According to Wall Street analysts Ajanta Pharma Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ajanta Pharma Limited pay dividends?

Ajanta Pharma Limited pays a Annually dividend of ₹28 which represents an annual dividend yield of 1.04%. See more information on Ajanta Pharma Limited dividends here

What is Ajanta Pharma Limited’s EPS estimate?

Ajanta Pharma Limited’s EPS estimate is 20.85.

How many shares outstanding does Ajanta Pharma Limited have?

Ajanta Pharma Limited has 124,935,620 shares outstanding.

What happened to Ajanta Pharma Limited’s price movement after its last earnings report?

Ajanta Pharma Limited reported an EPS of ₹21.8 in its last earnings report, beating expectations of ₹19.828. Following the earnings report the stock price went up 3.31%.

Which hedge fund is a major shareholder of Ajanta Pharma Limited?

Currently, no hedge funds are holding shares in IN:AJANTPHARM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ajanta Pharma Limited

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, pediatric, respiratory and general health products, dermatology, ophthalmology, and pain management areas. It also provides multivitamins, antibiotics, eye drops, cough syrups, etc. The company serves in India, Africa, rest of Asia, the United States, and internationally. It supplies its products to government bodies, including armed forces, government hospitals, canteens, stores department, etc. The company was founded in 1973 and is headquartered in Mumbai, India.

Ajanta Pharma Limited (AJANTPHARM) Earnings & Revenues

Historic Earnings Reports

AJANTPHARM Stock 12 Month Forecast

Average Price Target

₹3,207.50

▲(9.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2371":"₹2,371","2596":"₹2,596","2821":"₹2,821","3046":"₹3,046","3271":"₹3,271"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹3.27K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3207.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹3.21K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹3.15K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2371,2596,2821,3046,3271],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2787.15,2824.292307692308,2861.4346153846154,2898.5769230769233,2935.7192307692308,2972.8615384615387,3010.003846153846,3047.146153846154,3084.2884615384614,3121.4307692307693,3158.5730769230768,3195.7153846153847,3232.857692307692,{"y":3270,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2787.15,2819.4846153846156,2851.8192307692307,2884.153846153846,2916.4884615384617,2948.8230769230768,2981.1576923076923,3013.492307692308,3045.826923076923,3078.1615384615384,3110.496153846154,3142.830769230769,3175.1653846153845,{"y":3207.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2787.15,2814.6769230769232,2842.2038461538464,2869.7307692307695,2897.257692307692,2924.7846153846153,2952.3115384615385,2979.8384615384616,3007.3653846153848,3034.892307692308,3062.419230769231,3089.9461538461537,3117.473076923077,{"y":3145,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2668.48,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2459.92,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2586.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2670.91,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2526.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2477.82,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2664.53,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2424.87,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2372.11,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2436.83,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2560.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2936.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2787.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >